Skip to main
ACHV

ACHV Stock Forecast & Price Target

ACHV Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Achieve Life Sciences is a promising investment due to its potential for FDA approval, success in clinical trials for smoking cessation, and a large market for tobacco users. With a well-prepared commercial launch and plans for global expansion, the company has a strong outlook for growth and profitability. Valuation for the company is based on a risk-adjusted, DCF analysis of the opportunity for its new drug cytisinicline, which has shown impressive results in reducing cravings and withdrawal symptoms for both smoking and vaping.

Bears say

Achieve Life Sciences is a pre-revenue company with one product in late-stage clinical trials and lacks diversification in its pipeline. Despite positive results from their Phase 2 and Phase 3 trials for cytisinicline, uptake for this treatment may be slow and competition in the smoking cessation market is strong. In addition, Achieve Life Sciences is solely focused on addressing nicotine dependence, which limits their potential for growth and revenue diversification.

ACHV has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Achieve Life Sciences (ACHV) Forecast

Analysts have given ACHV a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACHV has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Achieve Life Sciences (ACHV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.